Brief: Kancera Reports Top-Line Data From Phase IIa-Study With Kand567 In COVID-19 Patients

Novakand Pharma AB

18/11/2021 14:04

Nov 18 (Reuters) - Kancera AB  KANC.ST :
    * REPORTS TOP-LINE DATA FROM PHASE IIA-STUDY WITH KAND567 IN COVID-19 PATIENTS
    * RADOMISED DOUBLE-BLINDED STUDY MET PRIMARY ENDPOINT
    * NO CONCLUSIONS COULD BE DRAWN REGARDING SECONDARY ENDPOINT
    * KAND567 PROVED TO HAVE FAVORABLE SAFETY AND TOLERABILITY PROFILE ALSO IN SEVERELY ILL
PATIENTS

Source text for Eikon:  ID:nMFNbBvcdT 
Further company coverage:  KANC.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))